Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598| Tel: +91 9167469649

August 30, 2023

To, BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400 001

Scrip Code : 531099

Sub : Outcome of Board Meeting

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Wednesday, August 30, 2023, inter alia, has considered and approved the following:

- 1. Approved notice calling of Annual General Meeting
- 2. Book Closure dates from September 24, 2023 till September 26, 2023 for the purpose of Annual General Meeting
- 3. The 32nd AGM of the Company is scheduled to be held on Saturday, September 30, 2023 at 10.00 a.m. (IST), through VC/OAVM facility to transact the business as set out in the Notice convening the AGM.
- 4. The e-voting period begins on September 27, 2023 at 10.00 a.m. and ends on September 29, 2023 at 5.00 p.m. During this period, shareholders of the Company holding shares as on the cut-off date i.e. September 23, 2023, may cast their vote electronically. The facility for e-voting will also be made available during the AGM to those members who could not cast their vote(s) by remote e-voting.
- 5. Results of AGM will be declared on October 3, 2023
- 6. Approval of related party transaction for the financial year 2023-24

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598| Tel: +91 9167469649

7. Based on the recommendation of the Nomination and Remuneration Committee, the Reappointment of Ms. Abha Kapoor as Whole Time Director of the Company for a further period of 3 year. This re-appointment is subject to the approval of the Shareholders of the Company.

Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given herein under: -

Disclosure Requirement	Details
Name of the Director	Abha Kapoor
Reason for change	For fulfillment of Composition of Board as
	per SEBI LODR
Date of appointment	Conclusion of Board Meeting held today
	subject to the approval of members of the
	Company
	Hay propert toning as Whale time Divertor
	Her present tenure as Whole-time Director
Term of Appointment	was expired on June 13, 2023. 3 years
Disclosure of relationship	Ms. Abha Kapoor is not related to any
between Directors inter-se	Director of the Company
Declaration	We confirm that Ms. Abha Kapoor is not
	debarred from holding the office of Director
	of the Company, by virtue of any SEBI
	order or any other such authority.
Names of listed entities in which	Checkpoint Trends Limited
the person also holds the	
directorship and the membership	
of Committees of the board	
along with listed entities from	
which the person has resigned in the past three years	
Shareholding of non-executive	NIL
directors	IAIL
nature of expertise in specific	Trading
functional areas;	3
Brief profile	Ms. Abha Kapoor is appointed as Whole-
	time Director of the Company.

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598| Tel: +91 9167469649

Ms. Abha Kapor is highly skillful and possesses vast experience in the field of Finance. She has over 15 years of experience in trading, construction and financce
She is not related to any other Director of the Company and is also not a Director in any other listed company. He or his relatives do not hold any shares in the Company.

8. Cession of Erstwhile Statutory auditor M/s. D D & Company due to expiry of their term pursuant to section 139 of Companies Act 2013.
Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given herein under: -

Disclosure Requirement	Details
Name	M/s. D D & Company
Reason for change	Expiry of the term
Date of cessation	August 22, 2023

9. Appointment of M/s. L K Ajmera & Associates as Statutory Auditors of the Company pursuant to section 139 of Companies Act 2013 Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given herein under: -

Disclosure Requirement	Details
Name of the auditor	M/s. L K Ajmera & Associates
Reason for change	Due to expiry of term of Erstwhile Statutory auditor
Date of appointment	In the ensuring AGM subject to the approval of members of the Company
Term of Appointment	5 years
Disclosure of relationship with	M/s. L K Ajmera & Associates is not related
Directors	to any Director of the Company
Declaration	We confirm that firm is duly qualified and
	eligible for this appointment and is not

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598| Tel: +91 9167469649

	disqualified for appointment under the provisions of sections 141 and 139 (2) of the Companies Act 2013, Rule 5 "of Companies (Audit and Auditors) Rules, 2014 and the Chartered Accountants Act, 1949, and Rules and Regulations made there under.
Brief profile	M/s. L K Ajmera & Associates, Chartered Accountants has experience of more than 2 decades of handling income tax, audit and GST practice.

The meeting commenced at 04.00 P.M. and concluded at 04.30 P.M.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Abha Kapoor

Director (Finance) and CFO

DIN - 02799429